1. Home
  2. IBRX vs SFNC Comparison

IBRX vs SFNC Comparison

Compare IBRX & SFNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IBRX
  • SFNC
  • Stock Information
  • Founded
  • IBRX 2014
  • SFNC 1903
  • Country
  • IBRX United States
  • SFNC United States
  • Employees
  • IBRX N/A
  • SFNC N/A
  • Industry
  • IBRX Biotechnology: Biological Products (No Diagnostic Substances)
  • SFNC Major Banks
  • Sector
  • IBRX Health Care
  • SFNC Finance
  • Exchange
  • IBRX Nasdaq
  • SFNC Nasdaq
  • Market Cap
  • IBRX 2.3B
  • SFNC 2.2B
  • IPO Year
  • IBRX N/A
  • SFNC N/A
  • Fundamental
  • Price
  • IBRX $2.44
  • SFNC $18.95
  • Analyst Decision
  • IBRX Strong Buy
  • SFNC Hold
  • Analyst Count
  • IBRX 5
  • SFNC 3
  • Target Price
  • IBRX $11.40
  • SFNC $23.33
  • AVG Volume (30 Days)
  • IBRX 7.6M
  • SFNC 2.2M
  • Earning Date
  • IBRX 08-05-2025
  • SFNC 07-17-2025
  • Dividend Yield
  • IBRX N/A
  • SFNC 4.49%
  • EPS Growth
  • IBRX N/A
  • SFNC 6.86
  • EPS
  • IBRX N/A
  • SFNC 1.27
  • Revenue
  • IBRX $56,600,000.00
  • SFNC $742,875,000.00
  • Revenue This Year
  • IBRX $567.98
  • SFNC $26.70
  • Revenue Next Year
  • IBRX $160.56
  • SFNC $7.88
  • P/E Ratio
  • IBRX N/A
  • SFNC $14.92
  • Revenue Growth
  • IBRX 4227.22
  • SFNC 2.18
  • 52 Week Low
  • IBRX $1.83
  • SFNC $17.20
  • 52 Week High
  • IBRX $7.48
  • SFNC $25.95
  • Technical
  • Relative Strength Index (RSI)
  • IBRX 40.38
  • SFNC 42.26
  • Support Level
  • IBRX $2.33
  • SFNC $18.48
  • Resistance Level
  • IBRX $2.46
  • SFNC $19.30
  • Average True Range (ATR)
  • IBRX 0.15
  • SFNC 0.44
  • MACD
  • IBRX -0.03
  • SFNC -0.12
  • Stochastic Oscillator
  • IBRX 14.10
  • SFNC 27.65

About IBRX ImmunityBio Inc.

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

About SFNC Simmons First National Corporation

Simmons First National Corp is a financial holding company. The company through its subsidiaries is engaged in providing banking services including consumer, real estate and commercial loans, checking, savings and time deposits. The company's loan portfolio comprises construction, single-family residential and commercial loans; non-real estate loans, nonaccrual and past due loans; and credit card loans, student loans and other consumer loans. It also offers various products and services such as trust services, investments, agricultural finance lending, equipment lending, insurance, consumer finance and small business administration lending. The business activity of the firm is functioned through the region of the United States.

Share on Social Networks: